Skip to main content
. 2009 Sep 24;5:757–766. doi: 10.2147/tcrm.s5189

Figure 2.

Figure 2

Efficacy of lacosamide (LCM) in partial epilepsy. Summary of the results of the phase-III studies of LCM as add-on treatment of patients with partial seizures with or without secondary generalization – primary endpoint 1: reduction in seizure frequency per 28 days from baseline to maintenance.

Notes: **P < 0.01 *P < 0.05